By Team INVC | INVC NEWS
Published: October 9, 2026 | 11 : 17 AM IST
NEW DELHI, India | October 9, 2026 — India’s cancer drug price cap targets the steep markups that can turn an already expensive prescription into a financial crisis for families. The government has approved a wider restriction on trade margins for non-scheduled anti-cancer medicines, with potential price reductions of up to 70%.
The Department of Pharmaceuticals said the measure could save patients approximately ₹2,500 crore annually. Under the approved framework, margins charged in the supply and sale of covered medicines will face a limit of 30% of the maximum retail price.
However, patients still need the final implementation details. An expert committee will identify the medicines, after which the National Pharmaceutical Pricing Authority will take a decision and issue its notification.
The approval therefore opens the way for lower prices. It does not establish an immediate, uniform discount on every cancer medicine.
The target: markups between the supply chain and the patient
The government’s intervention focuses on the difference between the price at which medicines move through the distribution chain and the retail price patients pay.
According to the department, NPPA’s market analysis found average markups of approximately 170% on non-scheduled anti-cancer medicines. In some cases, the markups reached 700% or more.
These figures describe the pricing concerns behind the decision. They do not mean that every cancer drug carries the same markup.
The department also reported substantial price differences between retail pharmacies, hospital pharmacies and online sellers.
For a family paying for repeated treatment cycles, those differences can accumulate. Consequently, the government wants to limit excessive margins before medicines reach patients.
Which cancer medicines will come under the new framework?
The approved expansion concerns non-scheduled anti-cancer medicines.
Scheduled medicines already come under government-set ceiling prices. The new approach extends price protection to additional cancer medicines by restricting their trade margins.
“Non-scheduled” describes a medicine’s position in the pricing framework. It does not mean the medicine lacks medical importance or regulatory approval.
The government said the intervention would span branded and generic products, domestic and imported medicines, and patented and non-patented categories.
Nevertheless, the expert committee under the Directorate General of Health Services must finalize the covered list. Patients cannot assume that a particular prescription qualifies until the authorities identify the relevant medicine and formulation.
A 30% margin cap is not a 30% discount
The two percentages in the announcement measure different things.
The 30% figure concerns the permitted trade margin, expressed in the official statement as a share of MRP. The potential reduction of up to 70% concerns how far some medicine prices could fall after the intervention.
Neither figure promises an identical reduction across all products.
The eventual change will depend on the medicine’s existing pricing and the notified framework. A product with a smaller existing margin may see a different adjustment from one with an exceptionally large markup.
Likewise, the projected ₹2,500 crore annual saving is an aggregate government estimate. It is not a fixed entitlement or reimbursement amount for each patient.
The 2019 intervention provides the precedent
The government has used this approach before.
In February 2019, NPPA capped trade margins on 42 selected non-scheduled anti-cancer medicines under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
The latest departmental statement says that intervention reduced some MRPs by up to 91% and generated reported annual savings of approximately ₹984 crore across 526 brands.
Those were outcomes of the earlier measure. They should not appear as guaranteed reductions under the newly approved expansion.
However, the precedent explains the government’s confidence that controlling distribution margins can provide substantial relief without treating every medicine as an identical product.
Availability remains part of the policy
Lower prices offer limited benefit if patients cannot obtain the medicines they need.
The department said manufacturers of non-scheduled anti-cancer medicines would have to maintain their current production levels.
That requirement accompanies the affordability measure. Its purpose is to preserve supply while the pricing framework changes.
The government’s statement does not provide a product-by-product assessment of availability. Consequently, patients and hospitals will need both the notified price details and information on actual supply.
What patients should check when the notification arrives
The next practical step is to match the final notification with the prescription.
Patients or caregivers should check the medicine name, strength, formulation, pack size and manufacturer. These details help determine whether a quoted price corresponds to the product covered by the order.
An itemized pharmacy bill can also help families separate medicine charges from other treatment expenses.
The policy concerns drug pricing. It does not promise an equivalent reduction in surgery, diagnostic tests, hospital stays or the entire treatment bill.
| Question | What the announcement establishes |
| Has the government approved the wider cap? | Yes, according to the Department of Pharmaceuticals. |
| What is the margin limit? | 30% of MRP under the announced framework. |
| Will every cancer medicine become 70% cheaper? | No. “Up to 70%” describes the potential reduction. |
| Is the final medicine list available in this statement? | No. The DGHS expert committee will finalize it. |
| What happens next? | NPPA will take a decision and issue the notification. |
| What are the projected annual savings? | Approximately ₹2,500 crore across patients. |
For families facing expensive prescriptions, the approval offers a prospect of relief. The decisive information will come next: which medicines qualify, what their revised prices will be and when those prices take effect.
